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Introduction: COVID-19 case fatality rate in hospitalized patients varies across countries 
and studies. Reliable estimates, specific for age, sex, and comorbidities, are needed to 
monitor the epidemic, to compare the outcome in different settings, and to correctly design 
trials for COVID-19 interventions. The aim of this study was to provide population-based 
survival curves of hospitalized COVID-19 patients.
Materials and Methods: A cohort study was conducted in three areas of Northern Italy, 
heavily affected by SARS-CoV-2 infection (Lombardy and Veneto Regions, and Reggio 
Emilia province), using a loco-regional COVID-19 surveillance system, linked to hospital 
discharge databases. We included all patients testing positive for SARS-CoV-2 RNA by RT- 
PCR on nasopharyngeal/throat swab samples who were hospitalized from 21 February to 
21 April 2020. Kaplan–Meier survival estimates were calculated at 14 and 30 days for death 
in any setting, stratifying by age, sex, and the Charlson Index.
Results: Overall, 42,926 hospitalized COVID-19 patients were identified. Patients’ median 
age was 69 years (IQR: 57–79), 62.6% were males, and 6.0% had a Charlson Index ≥3. 
Survival curves showed that 22.0% (95% CI 21.6–22.4) of patients died within 14 days and 
27.6% (95% CI 27.2–28.1) within 30 days from hospitalization. Survival was higher in 
younger patients and in females. The negative impact of comorbidities on survival was more 
pronounced in younger age groups.
Conclusion: The high fatality rate observed in the study (28% at 30 days) suggests that 
studies should focus on death as primary endpoint during a follow-up of at least one month.
Keywords: COVID-19, survival, cohort study, hospitalized patients, Italy
Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly on 
a global scale,1,2 with almost 24 million cases of coronavirus disease (COVID-19) being 
diagnosed worldwide.3 Italy was the first European country to be affected by COVID- 
19:3–5 as of 31 August 2020, more than 260,000 cumulative confirmed SARS-CoV-2 
infections were reported, with an overall case fatality rate (CFR) of 13.8%.6
Despite the fact that the body of relevant epidemiological findings about the pan-
demic has grown rapidly, COVID-19 CFR is still debated. Reports from different 
countries show considerable heterogeneity in CFR, ranging from less than 1% to 
approximately 12%.3,7 Differences in age and the burden of comorbidities of cases 
may partially explain these differences, but differences in case detection and reporting 
(denominator) and how COVID-19-related deaths are defined (numerator) are also 
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important sources of heterogeneity. In addition, the accuracy 
of CFR assessment is limited by disease ascertainment chal-
lenges, a bias in favor of including symptomatic and very sick 
patients, and variability in testing accuracy.8 Furthermore, the 
length of follow-up is essential to accurately measuring 
CFR.9–11
Two recent systematic reviews of trials and observational 
studies (mainly from China) found a pooled CFR estimate of 
3–4%;12,13 instead, most reports from European countries have 
shown CFRs ranging from 10% to 20% when a cohort 
approach with adequate follow-up was conducted.9,14 
Differences in CFR have also been reported in studies includ-
ing only hospitalized COVID-19 patients.15–19 Reliable popu-
lation-based estimates of CFR for hospitalized patients are 
essential for supporting clinical decision-making, providing 
standards to monitor the epidemic, and the performance of 
the health service. Furthermore, such a reference standard is 
needed to accurately design trials of interventions targeting 
COVID-19 with adequate statistical power and to give 
a counterfactual for Phase II, single-arm studies, a design that 
is often employed to test therapies in COVID-19 patients. As 
of 5 June 2020, 1163 interventional studies on COVID-19 
patients were registered on clinicaltrials.gov (Figure S1); of 
these, 38.4% were Phase II (including phase I/II and II/III) 
trials, and almost 50% of those studies were aimed at exploring 
survival as outcome (Figure S2). Given the rapid spread of the 
pandemic and the absence of any effective therapy, it is likely 
that new therapies, if proven to be promising in phase II 
studies, will be directly transferred to clinical practice without 
more rigorous testing of their efficacy in Phase III studies.
The aim of this study was therefore to provide popula-
tion-based survival curves of hospitalized COVID-19 
patients that can be used to monitor the impact of the 
epidemic and disease management as well as to design 
phase II trials and to correctly calculate the required sam-
ple size of phase III studies.
Materials and Methods
Setting
The study included patients living in the regions of Lombardy, 
the first and hardest hit Italian region (10 million inhabitants), 
and Veneto, where the second cluster was detected (4.9 million 
inhabitants), and Reggio Emilia province (0.5 million inhabi-
tants), which is part of the Emilia-Romagna region, which 
ranked second in terms of the spread of the epidemic during 
the study period. The three areas included in the study represent 
25% of the Italian population.
In Italy, the National Health Service provides all testing 
activities and acute care free of charge to all residents. All RT- 
polymerase chain reaction (PCR) SARS-CoV-2 tests per-
formed in Italy must be recorded in the national case-based 
integrated surveillance system of all RT-PCR-confirmed cases 
of COVID-19.14 This surveillance system contains data on all 
COVID-19 patients, collected by local public health depart-
ment during epidemiological investigations through: 1) daily 
reports from COVID-19 labs for all positive RT-PCR tests; 2) 
an initial epidemiological investigation conducted through 
phone interviews of all cases, followed by daily phone calls 
to patients cared for in outpatient settings carried out by the 
public health department of each local health authority; 3) daily 
reports extracted from electronic medical records for hospita-
lized patients, and 4) check of death records to assess mortality, 
particularly in outpatient settings (Figure S3). Although regio-
nal testing strategies differed due to local protocols and logistic 
constraints during the study period, patients in all the study 
areas with symptoms potentially suggesting COVID-19, who 
were admitted to the Emergency Room or hospital, were 
always tested.
Study Population
From the loco-regional COVID-19 integrated surveillance 
databases, all ≥18 years patients with confirmed SARS-CoV 
-2 infection who were hospitalized between 21 February (date 
of the first Italian COVID-19 patient hospitalization) and 
21 April 2020 were identified in Lombardy. Inclusion of all 
resident patients excluded any chance of selection bias. 
Patients hospitalized between 21 February and 
31 March 2020 were identified in the other two study areas 
(Veneto and Reggio Emilia), based on data availability at the 
time, the study analyses were carried out. The admission date 
was considered as the index date. Patients were followed up 
until death or the end of the study period (21 April 2020 for all 
the three areas), whichever came first. To calculate the 
Charlson Index20 for each hospitalized COVID-19 patient, 
hospital discharge databases were linked to the loco-regional 
COVID-19 surveillance database to identify all hospital admis-
sions within the 10 years preceding COVID-19 hospitaliza-
tions (Table S1); the use of pre-existing information avoided 
any ascertainment bias.
An R-based tool for distributed analyses (The ShinISS) 
developed by the Italian National Institute of Health was 
used by each study center to locally process COVID-19 
patient data using the same data model in all centers, and 
only an anonymized dataset for central analysis was 
shared, in compliance with EU-GDPR regulations.
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Outcome Measure
The endpoint was death occurring during follow-up in an 
inpatient or outpatient setting for any cause, as reported in the 
loco-regional COVID-19 surveillance system. The outcome 
measures were mortality at 14 and 30 days from hospital 
admission and time to event was calculated from COVID-19 
hospitalization to death or the end of follow-up, whichever 
came first.
Statistical Analysis
Univariate survival measures, with corresponding 95% con-
fidence intervals (95% CI), at a fixed follow-up time (14 and 30 
days) were computed with the Kaplan–Meier estimator for 
each covariate of interest: age (<50, 50–59, 60–69, 70–79, 
80–89, and ≥90 years), sex (males and females), and the 
Charlson Index (0, 1–2, and ≥3). Furthermore, we present 
data for sex and for the Charlson Index stratified by age 
category. A Cox proportional hazards model was used to 
show the adjusted effect of sex, age, comorbidities, the 
Charlson Index, and study area, with an interaction term 
between age and the Charlson Index. Proportional hazards 
assumptions were verified on the basis of Schoenfeld residuals 
and significance was set at p-value <0.05. All statistical ana-
lyses were performed using STATA (version 16) and 
R (version 3.6).
Results
The three loco-regional COVID-19 surveillance systems cap-
tured data from 79,822 patients, of whom 35,671 were 
excluded because they did not meet the inclusion criteria 
(being hospitalized or above 18 years old). A further 1225 
patients were excluded because their data could not be deter-
ministically linked to the resident population registries. 
Overall, 42,926 hospitalized COVID-19 patients were 
included in the study; of these, 38,715 (90.2%) were from 
Lombardy, 3229 (7.5%) were from Veneto, and 982 (2.3%) 
were from Reggio Emilia (Figure S3). Patients’ median age 
was 69 years (interquartile range, IQR: 57–79 years), and 
62.6% were males. The median time from hospitalization to 
death was 6 days (IQR: 3–12); 69.4% of patients did not have 
any prior hospitalization reporting the presence of comorbid-
ities included in the Charlson Index, while 6.0% had 
a Charlson Index ≥3 (Table 1).
Table 1 Baseline Patient Characteristics, Deaths, and Case Fatality Rate per 1000 Person-Days, by Study Area, Age, Sex, and the 
Charlson Index
All patients Person-time 
(days)
No. deaths CRF (per 1,000 p-d)
No. (%)
Total 42,926 1,016,708 11,205 11.02
Study area
Lombardy 38,715 90.2 965,129 10569 10.95
Veneto 3229 7.5 39,640 439 11.07
Reggio E. 982 2.3 11,939 197 16.50
Age, years
18-49 5561 13.0 159,252 141 0.89
50-59 7172 16.7 204,144 451 2.21
60-69 8754 20.4 233,431 1484 6.36
70-79 10,953 25.5 244,025 3867 15.85
80-89 8880 20.7 154,177 4343 28.17
≥90 1606 3.7 21,679 919 42.39
Gender
Males 26,873 62.6 635,776 7662 12.05
Females 16,053 37.4 380,932 3543 9.30
Charlson index
0 29,775 69.4 753,537 5805 7.70
1-2 10,575 24.6 220,501 4018 18.22
≥3 2576 6.0 42,670 1382 32.39
Abbreviation: No, number; CFR, Case Fatality Rate; p-d, person-days; Reggio E., Reggio Emilia.
Clinical Epidemiology 2020:12                                                                                               submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       
DovePress                                                                                                                       
1339
Dovepress                                                                                                                                                          Ferroni et al
The survival curves showed that 22.0% (95% CI 21.-
6–22.4%) and 27.6% (95% CI 27.2–28.1%) of patients 
died within 14 (Table S2) and 30 days from hospital 
admission, respectively (Table 2). The curve had similar 
trajectories for all age groups, although the survival rate 
was higher in patients aged <50 years (2.8% died at 30 
days) and those aged 50–59 years (6.7% died at 30 days). 
Instead, patients aged 80–89 years and ≥90 years had 
a lower survival rate (52.5% and 64.9% died at 30 days, 
respectively). Survival rates were also higher among 
females both at 14 and 30 days from admission (18.7% 
and 23.7%, respectively). The proportion of deaths occur-
ring at 30 days was higher in patients with comorbidities: 
20.7%, 40.2%, and 58.1% for those with a Charlson Index 
of 0, 1–2, and ≥3, respectively (Figure 1, Table 2).
The difference in survival between males and females 
was similar across all age groups (Tables S2 and 2, 
Figure S4), with the hazard ratio (HR) for females vs 
males equal to 0.66 (95% CI: 0.63–0.68) when adjusting 
for age, Charlson index, and study area (Table 3). The 
negative effect of comorbidities on survival was more 
pronounced in younger patients, and it gradually 
decreased with age as shown by the interaction terms 
below one (Table 3, Figure 2).
Discussion
In this large population-based cohort of Italian hospitalized 
COVID-19 patients, we observed a 27.6% fatality rate at 
one month from hospital admission. The fatality rate was 
slightly higher in males (29.9%) than in females (25.7%), 
Table 2 Proportion of Surviving Patients at 30 Days from Hospitalization, Estimated Using the Kaplan–Meier Survival Function, by 
Study Area, Age, Sex, and the Charlson Index
Cumulative survival rate % (95% CI)
All patients Age category
































































































































Abbreviation: 95% CI, 95% confidence interval; Reggio E., Reggio Emilia.
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and this difference dramatically increased in the oldest age 
groups. The burden of comorbidities, measured using the 
Charlson Index, was an important prognostic factor in 
younger patients, while its impact on fatality rate in patients 
aged ≥80 years was smaller, as probably the overall frailty 
of those patients was per se a very strong predictor of death.
We observed a much higher overall CFR in our study 
than did initial reports from other countries on hospitalized 
cohorts, where death rates rarely reached 20%.12,13,16 The 
variability in age structure and proportion of patients with 
comorbidities does not seem to explain all the observed 
differences in CFR across geographic areas. Several 
hypotheses have been proposed, including different viral 
strains causing more or less severe disease, differing capa-
cities of the healthcare systems to respond to the COVID- 
19 crisis as well as different case definitions, with some 
countries including probable cases in the overall death toll. 
The CFR can increase in some areas if there is a surge of 
infected patients, which adds to the strain on the healthcare 
system and can overwhelm its available medical 
resources.21 Recently, population-based studies from coun-
tries with a similar dynamic of the epidemic spread and 
Figure 1 Kaplan–Meier survival curves for hospitalized COVID-19 patients in Northern Italy, 21 February–21 April 2020. (A): overall; (B): stratified by age groups; (C): 
stratified by sex at birth; (D): stratified by the Charlson Index.
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Table 3 Risk of Death for Hospitalized COVID-19 Patients, Estimated Using Cox Proportional Hazards Models 
for Age, Sex, and Charlson Index. The Model is Adjusted for All Reported Variables and Study Area and Shows the 
Interaction Between Charlson Index and Age
HR (95% CI) 
Unadjusted
HR (95% CI) 
Adjusted
HR (95% CI) 
Adjusted*
Age, years





















































Sex x Charlson Index
Age 18–49 × CCI 0 ref
Age 50–59 × CCI 1–2 0.67  
(0.42–1.08)
Age 60–69 × CCI 1–2 0.53  
(0.34–0.81)
Age 70–79 × CCI 1–2 0.34  
(0.22–0.52)
Age 80–89 × CCI 1–2 0.31  
(0.20–0.48)
Age ≥90 × CCI 1–2 0.26  
(0.17–0.41)
Age 50–59 × CCI ≥3 0.46  
(0.20–1.08)
(Continued)
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similar age structure of the population showed CFRs com-
parable to our estimates. A study conducted in the UK on 
20,133 patients hospitalized for COVID-19 found a CFR 
of 26%.22 Data from hospitalized COVID-19 patients in 
New York City showed a CFR of 20% at approximately 
6 days of follow-up.18 This figure seems much higher than 
survival during the first week following hospitalization in 
our study; however, this fatality rate for the New York 
population, which showed an average Charlson Index>4, 
is consistent with our specific estimate for the population 
with a Charlson Index ≥3, which ranges from 20% to 25%. 
Two other studies from the US recently reported 17% in- 
Figure 2 Kaplan–Meier survival curves for hospitalized COVID-19 patients in Northern Italy stratified by age and the Charlson Index, 21 February–21 April 2020. (A): age 
18–49 years; (B): age 50–59 years; (C): age 60–69 years; (D): age 70–79 years; (E): age 80–89 years; (F): age 90+ years.
Table 3 (Continued). 
HR (95% CI) 
Unadjusted
HR (95% CI) 
Adjusted
HR (95% CI) 
Adjusted*
Age 60–69 × CCI ≥3 0.25  
(0.11–0.54)
Age 70–79 × CCI ≥3 0.13  
(0.06–0.28)
Age 80–89 × CCI ≥3 0.09  
(0.04–0.20)
Age ≥90 × CCI ≥3 0.07  
(0.03–0.16)
Notes: *Interpretation of HR with the interaction term: in the model with the interaction terms, the HRs of CCI decline with increasing age. For instance, the 
HR of CCI 3+ for the age class 50–59 is equal to the HR of CCI 3+ (15.2) multiplied by the interaction term of CCI 3+ and age class 50–59 (0.46) -> 15.2 × 0.46 
= 6.99. Similarly, HR for CCI 3+ and age 70–79 is equal to 15.2 × 0.13 = 1.98. 
Abbreviations: HR: hazard ratio; CI: confidence interval; ref.: reference; CCI: Charlson Comorbidity Index
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hospital mortality after 7 days of follow-up23 and 24% 
after 21 days.24 Thus, considering the possible bias that 
can lead to over or underestimation of CFR in cohort 
studies, the population-based nature of our study can 
exclude the possible bias due to selection of participant 
hospitals and that due to short and/or incomplete follow-up 
or assessment of in-hospital mortality only.
The impact of age on the risk of death was dramatic 
in our cohort, in line with all previous studies.7,14 The 
excess risk cannot be entirely attributed to the burden of 
comorbidities, usually more frequent in advanced age. 
In fact, comorbidities appear to be an important predic-
tor of death in COVID-19 patients in our cohort, in 
agreement with all previous epidemiologic 
investigations;16,17 however, their negative impact on 
survival is much more pronounced in younger than 
older patients. In our study design, the assessment of 
pre-existing comorbidities is independent from the out-
come as this information is collected through the analy-
sis of patient use of healthcare services in the years 
preceding the epidemic. Therefore, even if we may 
underestimate the presence of comorbidities, this mis-
classification is not differential in severe or fatal cases 
and in non-severe cases; the hazard ratios should thus be 
unbiased. On the other hand, because we included only 
hospitalized patients, our study may be affected by 
a selection bias that could lead to a collider effect. 
This bias can create associations that are not causal or 
may hide existing associations because some character-
istics can affect the probability of being hospitalized. In 
this case, it is possible that we underestimated the 
impact of comorbidities because they can increase the 
probability of being hospitalized more than the prob-
ability of dying of COVID-19; the net effect would 
thus inflate the denominator and dilute the fatality risk 
of people with comorbidity in this cohort.
The availability of life-sustaining therapies or the lack 
thereof should be considered when interpreting the 
COVID-19 mortality rate. Poor outcomes may be due to 
known risk factors such as old age, frailty, comorbidities, 
or profound disability, or because of effects of logistic 
limitations associated with the lack of medical staff and/ 
or medical staff burn-out, and/or lack of beds and/or of 
medical supplies. Moreover, although patients might 
indeed have SARS-CoV-2 infection, the infection itself 
may not necessarily be the cause of death, as in patients 
with metastatic cancer or terminal organ failure.25
Since the healthcare system in Italy is regionally based, 
the early response to the COVID-19 epidemic varied across 
regions. Thus, the observed differences in the spread of the 
infection in the study area were due both to the different size 
of the initial clusters, much larger in Lombardy, where there 
was already a widespread dissemination (in Codogno and 
Alzano/Nembro), than in Veneto (Vò Euganeo), and to the 
regional control strategies implemented.
Lombardy suffered the fastest progression of the epi-
demic and initially responded with a rapid intensification 
of regional surveillance through contact tracing and testing 
contacts of all positive cases, but it was not enough to 
contain the outbreaks. Therefore, in a “scenario of wide-
spread dissemination”,26 the objective shifted from con-
tainment to mitigation, with a strong action on expanding 
hospital services, including intensive care, to meet the 
increased need for hospitalization and ICUs beds.27 In 
Veneto, strict containment of the outbreak was initially 
successful, allowing contact tracing for the entire epidemic 
peak. Reggio Emilia, whose outbreak was related to the 
expansion of the cluster of Codogno, faced an “intermedi-
ate” situation between the two regions. As of 
21 April 2020, the proportion of positive tests out of the 
total number of swabs performed was 24.5% in Lombardy, 
6.1% in Veneto, and 17.1% in Emilia-Romagna.28
Moreover, clinical criteria that must be met for COVID- 
19 hospital admission may also vary among regions, princi-
pally due to a different organization of primary care and the 
availability of hospital beds, which varied in different places 
and moments of the epidemic, and the availability of other 
options for managing less severe patients, such as home- 
based treatment with monitoring. Where special units for 
home-based care for COVID-19 patients were activated, 
patients were treated and followed up at home, whenever 
possible. Nevertheless, CFRs in the three study areas became 
similar after an adequate follow-up (30 days), suggesting that 
regional differences in epidemic control strategies and in 
clinical criteria for hospital admission did not greatly affect 
our estimates, supporting the generalizability of the results.
Conclusion
In Northern Italy, during the peak of the epidemic (ie, 
February to April 2020), the case fatality rate of COVID- 
19 hospitalized patients at 30 days from admission was 
about 28%. Phase II clinical trials with follow-up shorter 
than 30 days from hospitalization may not capture all deaths 
related to COVID-19, ultimately leading to a potential 
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overestimation of the benefits for the investigated COVID- 
19 intervention in the absence of a comparator.
Reliable CFR and survival curves estimates should 
guide healthcare leaders and policymakers in developing 
public health strategies at national and international levels.
Abbreviations
SARS-CoV-2, severe acute respiratory syndrome corona-
virus 2; COVID-19, coronavirus disease; CFR, case fatal-
ity rate; PCR, polymerase chain reaction; 95% CI, 95% 
confidence intervals; IQR, interquartile range; HR, hazard 
ratio; No, number; ref, reference; CCI, Charlson Index.
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